MARCHF5 and breast cancer: Figure 1D shows the different frequencies of alterations in co-occurring genes. Figure 1E shows and overview of clinical attributes and scatter plots of mutation counts and genomic alteration scores for each case in the TCGA breast cancer study (Figure 1E). In addition, significant changes in MARCH5 gain and loss are observed in the CNV ratio distribution and box line plots (Figure 1F). Similarly, when we looked at MARCH5 expression in all cancer types, we observed high levels of MARCH5 expression in breast cancer tumor tissues compared with normal tissues at Chr10:92353894 (Figure 1G).